Chinese Domestic Alliances Focus On China-Only Rights As Confidence Grows
Executive Summary
Confidence in growing in-house commercial capabilities has recently prompted several Chinese pharmas, including Simcere and 3SBio, to focus on obtaining domestic rights to novel drug assets developed by other China-based biotechs, rather than pursuing international deals.